BioPharmSignal logoBioPharmSignal

Company Profile

Maia Biotechnology Stock Price, News & Analysis

Ticker:
MKT
Exchange:
NYSE
Sector:
Biopharma
Location:
United States

Why the stock is moving

Current closing-price context is not available for MKT.

Company overview

Business overview

Maia Biotechnology is an oncology company focused on precision cancer therapies and targeted treatment approaches. Its story centers on developing differentiated medicines for difficult cancers.

Geographic Base and Sector Classification

Maia Biotechnology is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.

Business Model Characteristics

The company depends on clinical data, translational confidence, and the ability to fund a narrow cancer pipeline. Investors usually watch proof-of-concept and strategic positioning.

Position Within the Biotechnology Landscape

Maia occupies a focused oncology niche within biotech. It is a catalyst-sensitive name where the market needs evidence that the programs can matter clinically.

Future catalysts

Maia Biotechnology’s catalysts are THIO-related oncology programs, plus any update that clarifies whether the company can keep the DNA-damage strategy alive. The market will care about actual clinical progress.

Recent news

  1. 01

    MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

    Source: Maia Biotechnology

  2. 02

    MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

    Source: Maia Biotechnology

  3. 03

    MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University

    Source: Maia Biotechnology

  4. 04

    MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial

    Source: Maia Biotechnology

  5. 05

    MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial

    Source: Maia Biotechnology

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

KZIA

Kazia Therapeutics Limited

CGON

CG Oncology, Inc.

APTO

Aptose Biosciences, Inc.

AURA

Aura Biosciences

PPBT

Purple Biotech

TNGX

Tango Therapeutics

MURA

Mural Oncology

ALLR

Allarity Therapeutics

Frequently Asked Questions

What does Maia Biotechnology do?

Maia Biotechnology is an oncology company focused on precision cancer therapies and targeted treatment approaches. Its story centers on developing differentiated medicines for difficult cancers.

On which exchange is MKT stock listed?

Maia Biotechnology (MKT) is associated with NYSE, United States, Biopharma.

What is Maia?

Maia Biotechnology’s catalysts are THIO-related oncology programs, plus any update that clarifies whether the company can keep the DNA-damage strategy alive.

Which conditions is Maia Biotechnology targeting with Maia?

Maia Biotechnology is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.

How does Maia Biotechnology describe recent progress with Maia?

Maia Biotechnology’s catalysts are THIO-related oncology programs, plus any update that clarifies whether the company can keep the DNA-damage strategy alive.

What is Biotechnology?

Maia Biotechnology is an oncology company focused on precision cancer therapies and targeted treatment approaches.

What should investors watch for with Biotechnology?

Maia Biotechnology’s catalysts are THIO-related oncology programs, plus any update that clarifies whether the company can keep the DNA-damage strategy alive.

What is THIO-related?

Maia Biotechnology’s catalysts are THIO-related oncology programs, plus any update that clarifies whether the company can keep the DNA-damage strategy alive.